Monday, March 4, 2024
HomeBusinessCovid Pfizer (PFE) earnings Q1 2022

Covid Pfizer (PFE) earnings Q1 2022


Albert Bourla, chief government officer of Pfizer pharmaceutical firm, arrives to ring the closing bell on the New York Inventory Change.

Drew Angerer | Getty Photographs

Pfizer beat on its prime and backside line in its first quarter earnings report, pushed by sturdy gross sales of its Covid vaccine and oral antiviral remedy.

The pharmaceutical large stated it offered $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral remedy Paxlovid within the first quarter.

Here is how Pfizer carried out in comparison with what Wall Road anticipated, primarily based on analysts’ common estimates compiled by Refinitiv:

  • Adjusted EPS: $1.62 per share, vs. $1.47 anticipated
  • Income: $25.66 billion, vs. $23.86 billion anticipated

Shares of Pfizer have been successfully flat in premarket buying and selling.

The corporate reaffirmed its full-year 2022 steerage of $32 billion in Covid vaccine gross sales and $22 billion for Paxlovid.

CNBC Well being & Science

Learn CNBC’s newest international protection of the Covid pandemic:

This can be a growing story. Please verify again for updates.



Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments